Travere Therapeutics, Inc. (TVTX)

Market Cap	2.84B +56.9%
Revenue (ttm)	490.73M +110.5%
Net Income	-25.55M
EPS	-0.29
Shares Out	92.37M
PE Ratio	n/a
Forward PE	19.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,501,793
Open	28.69
Previous Close	28.96
Day's Range	28.38 - 31.71
52-Week Range	13.88 - 42.13
Beta	0.87
Analysts	Strong Buy
Price Target	37.08 (+20.78%)
Earnings Date	Apr 30, 2026

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urin...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Eric Dube
• Employees: 497
• Stock Exchange: NASDAQ
• Ticker Symbol: TVTX
• Website: https://travere.com

Financial Performance

In 2025, Travere Therapeutics's revenue was $490.73 million, an increase of 110.45% compared to the previous year's $233.18 million. Losses were -$25.55 million, -92.06% less than in 2024.

Analyst Summary

According to 13 analysts, the average rating for TVTX stock is "Strong Buy." The 12-month stock price target is $37.08, which is an increase of 20.78% from the latest price.

Price Target

$37.08

(20.78% upside)

Analyst Consensus: Strong Buy